RecruitingPhase 3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Sponsor: Merck Sharp & Dohme LLCChattanooga, TN · Knoxville, TN · Memphis, TN · +51 more sites
RecruitingPhase 3NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Sponsor: Merck Sharp & Dohme LLCKnoxville, TN · Nashville, TN · +61 more sites
RecruitingPhase 3NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Sponsor: Merck Sharp & Dohme LLCKnoxville, TN · +29 more sites
RecruitingPhase 2NCT07002034RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesSponsor: Reunion Neuroscience IncKnoxville, TN · +31 more sites